Top 3 Genomics Stocks to Consider for Your Portfolio

Key Takeaways EDIT advances CRISPR-based EDIT-401, showing over 90% LDL-C reduction in preclinical tests.SANA pushes ex vivo and in vivo platforms, with IND plans for SC451 in 2026 and SG293 in 2027.PACB delivers advanced long-read sequencing tools serving research, clinical and commercial users.An updated edition of the Sept. 18, 2025, article.Genomics is a comprehensive study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Given the recent promising breakthroughs in this field, th ...